Jeevan Rekha: Combating Hepatitis C in Haryana

Dr. Parveen Malhotra, Singh I, Malhotra V, Malhotra N

Dr. Parveen Malhotra, Singh I, Malhotra V, Malhotra N

Keywords: Hepatitis C virus, Sustained Virological response, Compliance rate, Genotype

Abstract

Introduction: Hepatitis C is a contagious liver disease that results from infection with the hepatitis C virus. Progression from acute to chronic HCV infection occurs in 50% to 85% of cases. Hepatitis C virus (HCV) is a major cause of liver disease worldwide and a potential cause of substantial morbidity and mortality in the future.
Aims and Objectives: To study the effectiveness of the Jeevan Rekha Scheme (State Sponsored Scheme) in combating the menace of chronic hepatitis C in the state of Haryana- India.
Material and Methods: The patients who were anti-HCV positive and subsequently confirmed on HCV RNA (quantitative) and genotyping were treated with Pegylated Interferon and Ribavirin and followed up serially for viral loads at repeated intervals, till they reached stage of sustained virological response.
Results: Majority of the subjects were male and belonged to younger age group. Genotype 3 was most common, followed by 4 and 1. The compliance rate was excellent i.e.,93%. The overall sustained virological response was very high i.e., 90%.

References

1. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care. 2005;11(10):S286-S295.
2. Lavanchy D. Evolving epidemiology of Hepatitis C Virus. Clin Microbiol Infect. 2011;17:107–115
3. Sood A, Sarin SK, Midha M et al. Prevalence of hepatitis C virus in a selected geographical area. of northern India: a population based survey. Indian J Gastroenterol. 2012;31(5):232–236
4. Medhi S, Goswami B, Das A et al. New insights into hepatitis C virus infection in the tribal-dominant part of Northeast India. Arch Virol. 2012;157:2083–2093.
5. National Summary Report – India (July 2011), Integrated Behavioral and Biological Assessment (IBBA), Round 2 (2009-2010). New Delhi: Indian Council of Medical Research and FHI 360.
6. Chelleng PK, Borkakoty BJ, Chetia M, Das HK, Mahanta J. Risk of Hepatitis C infection among injection drug users in Mizoram. Indian J Med Res. 2008;128:640-646
7. Mukhopadhya A. Hepatitis C in India. J. Biosci. 2008; 33:465-473.
8. Sievert W, Altraif I, Razavi HA et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(2):61-80.
9. Narahari S, Juwle A, Basak S and Saranath D. Prevalence and geographic distribution of Hepatitis C Virus genotypes in Indian patient cohort. Infection, Genetics and Evolution. 2009;9:643–645